{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:28:12Z","timestamp":1758630492671,"version":"3.37.3"},"reference-count":23,"publisher":"Bentham Science Publishers Ltd.","issue":"8","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100009388","name":"Deanship of Scientific Research, Jazan University","doi-asserted-by":"publisher","award":["38\/08\/398"],"award-info":[{"award-number":["38\/08\/398"]}],"id":[{"id":"10.13039\/100009388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2020,7,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Sorafenib is the first oral therapeutic agent to show the activity against human\nhepatocellular carcinoma. Sorafenib leads to severe toxicity due to the multiple-dose regimen. Reducing\nthe overall dose of sorafenib through injectable dosage form to release sustainably is of therapeutically\nmore important to combat drug-induced toxicity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The purpose of this study was to formulate and evaluate the physical parameters of sorafenib-\nloaded Sodium Selenite Nanoparticles (SSSNP).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Two different methods: chemical crosslinking and solvent evaporation were applied for the\nformulation of nanoparticles using various crosslinkers such as formaldehyde, magnesium sulfate,\ntripolyphosphate, dextran sulfate, and aluminum hydroxide. Physical characterization was performed\nwith zeta potential analysis, polydispersity index, particle size and scanning electron microscopic studies\nfor morphological analysis for all the formulated nanoparticles developed using the chemical crosslinking\ntechnique based ionic interaction.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Tripolyphosphate was selected as an ideal crosslinker and used for nanoparticle formulation\nwith the solvent evaporation technique. Based on the physical characterization, SSSNP was formulated\nsuccessfully with the solvent evaporation technique using tripolyphosphate as a cross-linker. The zeta\npotential of SSSNP was -37.5 mV, PDI was approximately 0.3 to 0.4, and the observed size (diameter)\nwas in the range of 208 nm to 0.2 \u03bcm. Furthermore, the particles were smooth in morphology and appeared\nas crystals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The novel injectable sorafenib loaded sodium selenite nanoparticle dosage form will\nserve better than conventional oral dosage form to elicit a safe therapeutic effect.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201021666191230124041","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T14:11:02Z","timestamp":1577715062000},"page":"659-666","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-0166","authenticated-orcid":true,"given":"Sivakumar S.","family":"Moni","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad F.","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed M.","family":"Safhi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad H.","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz A.","family":"Makeen","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Research Unit, Clinical Pharmacy Department, Faculty of Pharmacy, Jazan University, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed E.","family":"Elmobark","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"Dong, Ju;","year":"2019","unstructured":"Dong, Ju;; Yang J.D.; Hainaut P.; Gores G.J.; Amadou A.; Plymoth A.; Roberts L.R.; A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019,16(10),589-604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=2","first-page":"1","author":"Sulieman A.","year":"2015","unstructured":"Sulieman A.; Ali A.; Shouki B.; Hani A.; Hind A.; Khaled S.;  Cancer Incidence Report Saudi ArabiaKingdom of Saudi Arabia Saudi Health Council National Health Information Center Saudi Cancer Registry 2015,1-84","journal-title":"Cancer Incidence Report Saudi ArabiaKingdom of Saudi Arabia Saudi Health Council National Health Information Center Saudi Cancer Registry"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2174\/15680266113136660197","volume":"13","author":"Pejin B.","year":"2013","unstructured":"Pejin B.; Jovanovi\u0107 K.K.; Mojovi\u0107 M.; Savi\u0107 A.G.; New and highly potent antitumor natural products from marine-derived fungi: Covering the period from 2003 to 2012. Curr Top Med Chem 2013,13(21),2745-2766","journal-title":"Curr Top Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1080\/14786419.2018.1425854","volume":"33","author":"Pejin B.","year":"2019","unstructured":"Pejin B.; Glumac M.; New cytotoxic natural products from the mangrove biome: Covering the period 2007-2015. Nat Prod Res 2019,33(11),1624-1628","journal-title":"Nat Prod Res"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0109-6","volume":"7","author":"Medavaram S.","year":"2018","unstructured":"Medavaram S.; Zhang Y.; Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol 2018,7(17)","journal-title":"Exp Hematol Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/MCG.0000000000001085","volume":"53","author":"Leathers J.S.","year":"2019","unstructured":"Leathers J.S.; Balderramo D.; Prieto J.; Diehl F.; Gonzalez-Ballerga E.; Ferreiro M.R.; Carrera E.; Barreyro F.; Diaz-Ferrer J.; Singh D.; Mattos A.Z.; Carrilho F.; Debes J.D.; Sorafenib for treatment of hepatocellular carcinoma: A survival analysis from the South American liver research network. J Clin Gastroenterol 2019,53(6),464-469","journal-title":"J Clin Gastroenterol"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"Bosch F.X.","year":"2004","unstructured":"Bosch F.X.; Ribes J.; D\u00edaz M.; Cl\u00e9ries R.; Primary liver cancer: Worldwide incidence and trends. Gastroenterology, ,(Suppl. 1), S5-S16.2004,127(5)","journal-title":"Gastroenterology,"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"Wilhelm S.M.","year":"2004","unstructured":"Wilhelm S.M.; Carter C.; Tang L.; Wilkie D.; McNabola A.; Rong H.; Chen C.; Zhang X.; Vincent P.; McHugh M.; Cao Y.; Shujath J.; Gawlak S.; Eveleigh D.; Rowley B.; Liu L.; Adnane L.; Lynch M.; Auclair D.; Taylor I.; Gedrich R.; Voznesensky A.; Riedl B.; Post L.E.; Bollag G.; Trail P.A.; BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004,64(19),7099-7109","journal-title":"Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1208\/aapsj0902015","volume":"9","author":"Torchilin V.P.","year":"2007","unstructured":"Torchilin V.P.; Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007,9(2),E128-E147","journal-title":"AAPS J"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtemb.2011.06.001","volume":"25","author":"Liping F.","year":"2011","unstructured":"Liping F.; Qiong Liu.; Liming S.; Liming S.; Proteomic study on sodium selenite-induced apoptosis of human cervical cancer HeLa cells. J Trace Elem Med Biol 2011,25(3),130-137","journal-title":"J Trace Elem Med Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","volume":"99","author":"Minami H.","year":"2008","unstructured":"Minami H.; Kawada K.; Ebi H.; Kitagawa K.; Kim Y.I.; Araki K.; Mukai H.; Tahara M.; Nakajima H.; Nakajima K.; Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008,99(7),1492-1498","journal-title":"Cancer Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/10717544.2018.1561766","volume":"26","author":"Wang H.","year":"2019","unstructured":"Wang H.; Sun S.; Zhang Y.; Wang J.; Zhang S.; Yao X.; Chen L.; Gao Z.; Xie B.; Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles. Drug Deliv 2019,26(1),89-97","journal-title":"Drug Deliv"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijpharm.2011.08.003","volume":"419","author":"Wang X.Q.","year":"2011","unstructured":"Wang X.Q.; Fan J.M.; Liu Y.O.; Zhao B.; Jia Z.R.; Zhang Q.; Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm 2011,419(1-2),339-346","journal-title":"Int J Pharm"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-7-91","volume":"7","author":"Kim D.H.","year":"2012","unstructured":"Kim D.H.; Kim M.D.; Choi C.W.; Chung C.W.; Ha S.H.; Kim C.H.; Anti-tumor activity of sorafenib incorporated nanoparticles of dextran \/ poly(dl-lactide-co-glycolide) block copolymer. Nanoscale Res Lett 2012,7(1),1-6","journal-title":"Nanoscale Res Lett"},{"key":"ref=15","first-page":"4245","volume":"8","author":"Abouelhag H.A.","year":"2017","unstructured":"Abouelhag H.A.; Sivakumar S.M.; Bagul U.S.; Mohamed E.; Safhi M.M.; Preparation and physical characterization of cisplatin chitosan nanoparticles by zeta nano sizer \u201cprime step for formulation and development\u201d. IJPSR 2017,8(10),4245-4249","journal-title":"IJPSR"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.taap.2008.06.009","volume":"232","author":"Clift M.J.","year":"2008","unstructured":"Clift M.J.; Rothen-Rutishauser B.; Brown D.M.; Duffin R.; Donaldson K.; Proudfoot L.; Guy K.; Stone V.; The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol 2008,232(3),418-427","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"6940","DOI":"10.1021\/la049524t","volume":"20","author":"Ito T.","year":"2004","unstructured":"Ito T.; Sun L.; Bevan M.A.; Crooks R.M.; Comparison of nanoparticle size and electrophoretic mobility measurements using a carbon-nanotube-based coulter counter, dynamic light scattering, transmission electron microscopy, and phase analysis light scattering. Langmuir 2004,20(16),6940-6945","journal-title":"Langmuir"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"Hare J.I.","year":"2017","unstructured":"Hare J.I.; Lammers T.; Ashford M.B.; Puri S.; Storm G.; Barry S.T.; Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev 2017,108,25-38","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"Senapati S.","year":"2018","unstructured":"Senapati S.; Mahanta A.K.; Kumar S.; Maiti P.; Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 2018,3(7),7","journal-title":"Signal Transduct Target Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijpharm.2018.02.007","volume":"540","author":"Aftab S.","year":"2018","unstructured":"Aftab S.; Shah A.; Nadhman A.; Kurbanoglu S.; Ays\u0131l Ozkan S.; Dionysiou D.D.; Shukla S.S.; Aminabhavi T.M.; Nanomedicine: An effective tool in cancer therapy. Int J Pharm 2018,540(1-2),132-149","journal-title":"Int J Pharm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2217\/nnm.16.5","volume":"11","author":"Hoshyar N.","year":"2016","unstructured":"Hoshyar N.; Gray S.; Han H.; Bao G.; The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond) 2016,11(6),673-692","journal-title":"Nanomedicine (Lond)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1002\/anie.201403036","volume":"53","author":"Sun T.","year":"2014","unstructured":"Sun T.; Zhang Y.S.; Pang B.; Hyun D.C.; Yang M.; Xia Y.; Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 2014,53(46),12320-12364","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"Jain R.K.","year":"2010","unstructured":"Jain R.K.; Stylianopoulos T.; Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010,7(11),653-664","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T09:52:27Z","timestamp":1600768347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177899\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201021666191230124041","relation":{},"ISSN":["1389-2010"],"issn-type":[{"type":"print","value":"1389-2010"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}